$145.90
-0.92[-0.63%]
At close: Apr 26
$145.90
0[0.00%]
After Hours: 6:00PM EDT
Johnson & Johnson
(NYSE:JNJ)Latest News for Johnson & Johnson Stock (NYSE:JNJ)
Johnson & Johnson Stock (NYSE: JNJ)
Categories: All
Wednesday, April 24, 2024
Tuesday, April 23, 2024
Monday, April 22, 2024
Friday, April 19, 2024
Thursday, April 18, 2024
Wednesday, April 17, 2024
- Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About FutureVandana Singh - Apr 17, 2024, 3:37PM
- Johnson & Johnson Analysts Cut Their Forecasts After Q1 ResultsAvi Kapoor - Apr 17, 2024, 1:51PM
- RBC Capital Maintains Outperform on Johnson & Johnson, Lowers Price Target to $175Benzinga Newsdesk - Apr 17, 2024, 1:11PM
- Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price TargetBenzinga Newsdesk - Apr 17, 2024, 9:28AM
- Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For WednesdayAvi Kapoor - Apr 17, 2024, 8:21AM
- B of A Securities Maintains Neutral on Johnson & Johnson, Lowers Price Target to $170Benzinga Newsdesk - Apr 17, 2024, 6:33AM
Tuesday, April 16, 2024
- Stocks Grapple With Geopolitical Pressures, Gold Eyes $2,400, Bitcoin Falls Below $62,000: What's Driving Markets Tuesday?Piero Cingari - Apr 16, 2024, 1:28PM
- Johnson & Johnson shares are trading lower after the company issued 2024 guidance.Benzinga Newsdesk - Apr 16, 2024, 1:10PM
- Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit SpinoffUpwallstreet - Apr 16, 2024, 11:49AM
- Johnson & Johnson Q1 Earnings Top Wall Street Estimates On Strong Medical Devices Sales, Drugmaker Boosts Annual OutlookVandana Singh - Apr 16, 2024, 9:29AM
- Wall Street Braces For Mixed Open As Middle-East Tensions Offset Earnings Optimism: Analyst Points To Silver Lining In Rally BreakShanthi Rexaline - Apr 16, 2024, 7:24AM
- Earnings Scheduled For April 16, 2024Benzinga Insights - Apr 16, 2024, 6:53AM
- Johnson & Johnson Has Declared 4.2% Increase In Quarterly Dividend, From $1.19 Per Share To $1.24 Per ShareBenzinga Newsdesk - Apr 16, 2024, 6:29AM
- Johnson & Johnson Forecast Fiscal Year 2024 Operational Sales Of $88.7B-$89.1B Versus Prior Guidance Of $88.2B–$89.0B And Consensus $88.43BBenzinga Newsdesk - Apr 16, 2024, 6:28AM
- Johnson & Johnson Expects 2024 Adjusted EPS Of $10.57–$10.72 Versus Consensus Of $10.66 And Prior Guidance Of $10.55–$10.75, With Adjusted Operational EPS Of $10.60–$10.75Benzinga Newsdesk - Apr 16, 2024, 6:26AM
- Johnson & Johnson Q1 2024 Adj EPS $2.71 Beats $2.64 Estimate, Sales $21.383B Miss $21.398B EstimateBenzinga Newsdesk - Apr 16, 2024, 6:22AM
- Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsAvi Kapoor - Apr 16, 2024, 2:15AM
- Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into TuesdayAvi Kapoor - Apr 16, 2024, 2:10AM
- Fear & Greed Index Moves To 'Fear' Zone; S&P 500 Down Over 1%Avi Kapoor - Apr 16, 2024, 2:09AM
Monday, April 15, 2024
- J&J Braces For Q1 Earnings With Bearish Charts And Patent Cliffs In PlaySurbhi Jain - Apr 15, 2024, 4:47PM
- Medical Device Manufacture Integer To Gain From Expanding Pulsed Field Ablation Market, Earns Upgrade From BofAVandana Singh - Apr 15, 2024, 2:42PM
- A Closer Look at 9 Analyst Recommendations For Johnson & JohnsonBenzinga Insights - Apr 15, 2024, 11:01AM
- Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price TargetBenzinga Newsdesk - Apr 15, 2024, 10:30AM
Friday, April 12, 2024
Thursday, April 11, 2024
Wednesday, April 10, 2024
Tuesday, April 09, 2024
Monday, April 08, 2024
- Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider PopulationVandana Singh - Apr 8, 2024, 2:19PM
- Johnson & Johnson's $13B Shockwave Medical Deal Accelerates MedTech Strategy, Analyst SaysVandana Singh - Apr 8, 2024, 1:27PM
- Shockwave Medical Stock Rises After Johnson & Johnson BuyoutMarketBeat - Apr 8, 2024, 1:23PM
- Reported Friday, Johnson & Johnson's CARVYKTI Approved By The U.S. FDA For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received At Least One Prior Line Of TherapyBenzinga Newsdesk - Apr 8, 2024, 3:30AM
Friday, April 05, 2024
- Johnson & Johnson Makes Yet Another Multi-Billion MedTech Deal With Shockwave MedicalVandana Singh - Apr 5, 2024, 8:35AM
- Johnson & Johnson Agrees To Acquire Shockwave Medical For $335/Share In Cash, Corresponding To An Enterprise Value Of Approximately $13.1B Including Cash AcquiredBenzinga Newsdesk - Apr 5, 2024, 6:33AM
Thursday, April 04, 2024
- Johnson & Johnson Recommends Shareholders Reject Mini-Tender Offer By TRC Capital InvestmentBenzinga Newsdesk - Apr 4, 2024, 6:03PM
- 10 Health Care Stocks Whale Activity In Today's SessionBenzinga Insights - Apr 4, 2024, 1:35PM
- Odyssey Therapeutics Earlier Announced Strategic Collaboration With Janssen Pharmaceuticals to Advance AI-Driven Small Molecule Drug DiscoveryCharles Gross - Apr 4, 2024, 7:58AM
Wednesday, April 03, 2024
Monday, April 01, 2024
Thursday, March 28, 2024
Wednesday, March 27, 2024
- Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says AnalystVandana Singh - Mar 27, 2024, 4:23PM
- "Johnson & Johnson Will Get A New Chance To Contest The Scientific Evidence Linking Talc Products To Ovarian Cancer, A Federal Judge Ruled On Wednesday, Potentially Disrupting A Federal Court Case That Consolidates 53,000 Lawsuits"Benzinga Newsdesk - Mar 27, 2024, 3:38PM